MAIA Biotechnology (MAIA) EBT (2021 - 2026)

MAIA Biotechnology (MAIA) has reported EBT for 6 consecutive years, with -$8.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 63.52% year-over-year to -$8.3 million in Q2 2026; TTM through Jun 2026 was -$28.9 million, a 48.92% decrease from a year earlier, with the FY2025 full-year figure at -$24.3 million, down 45.86% from the prior year.
• EBT was -$8.3 million for Q2 2026 at MAIA Biotechnology, down from -$6.9 million in the prior quarter.
• Over five years, EBT peaked at -$3.4 million in Q2 2022 and troughed at -$9.4 million in Q3 2025.
• A 5-year average of -$5.1 million and a median of -$4.8 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT increased 22.41% in 2024 and tumbled 129.3% in 2025, its largest moves.
• Over 5 years, EBT stood at -$4.2 million in 2022, then plunged by 51.14% to -$6.3 million in 2023, then advanced by 22.41% to -$4.9 million in 2024, then gained by 12.34% to -$4.3 million in 2025, then slumped by 92.65% to -$8.3 million in 2026.
• The last three EBT figures came in at -$8.3 million (Q2 2026), -$6.9 million (Q1 2026), and -$4.3 million (Q4 2025), per Business Quant data.